C WorldWide Group Holding A S Sells 3,054 Shares of Elevance Health, Inc. $ELV

C WorldWide Group Holding A S trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV) by 3.4% during the third quarter, HoldingsChannel reports. The firm owned 88,000 shares of the company’s stock after selling 3,054 shares during the quarter. Elevance Health comprises 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 27th largest holding. C WorldWide Group Holding A S’s holdings in Elevance Health were worth $28,435,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ELV. High Ground Investment Management LLP raised its stake in Elevance Health by 19.1% during the 3rd quarter. High Ground Investment Management LLP now owns 289,232 shares of the company’s stock worth $93,457,000 after buying an additional 46,390 shares during the period. ABN AMRO Bank N.V. increased its holdings in shares of Elevance Health by 1.2% in the third quarter. ABN AMRO Bank N.V. now owns 36,528 shares of the company’s stock worth $11,749,000 after acquiring an additional 448 shares in the last quarter. HighPoint Advisor Group LLC raised its position in shares of Elevance Health by 25.0% during the third quarter. HighPoint Advisor Group LLC now owns 4,541 shares of the company’s stock worth $1,467,000 after purchasing an additional 909 shares during the period. HORAN Wealth LLC bought a new position in shares of Elevance Health during the 3rd quarter valued at about $385,000. Finally, Bessemer Group Inc. lifted its holdings in shares of Elevance Health by 5.9% during the 3rd quarter. Bessemer Group Inc. now owns 147,372 shares of the company’s stock valued at $47,619,000 after purchasing an additional 8,152 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Up 0.5%

Shares of ELV stock opened at $340.34 on Thursday. The firm’s fifty day moving average price is $352.02 and its two-hundred day moving average price is $329.67. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The firm has a market capitalization of $75.64 billion, a P/E ratio of 13.55, a PEG ratio of 1.89 and a beta of 0.50.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same quarter last year, the company earned $3.84 EPS. Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is currently 27.23%.

Analysts Set New Price Targets

ELV has been the subject of a number of research reports. Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Guggenheim lowered their price objective on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Barclays cut their price objective on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Bank of America increased their target price on Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Finally, The Goldman Sachs Group began coverage on Elevance Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price target on the stock. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.